Compare DSGN & ZSQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSGN | ZSQR |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 853.8M | 697.4M |
| IPO Year | 2021 | 2020 |
| Metric | DSGN | ZSQR |
|---|---|---|
| Price | $15.48 | $4.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $15.25 | N/A |
| AVG Volume (30 Days) | ★ 469.6K | 346.4K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.27 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,363,045.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.10 | $3.53 |
| 52 Week High | $17.25 | $16.62 |
| Indicator | DSGN | ZSQR |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 38.34 |
| Support Level | $9.78 | $3.77 |
| Resistance Level | $15.99 | $4.25 |
| Average True Range (ATR) | 0.63 | 0.34 |
| MACD | 0.09 | 0.24 |
| Stochastic Oscillator | 74.09 | 83.12 |
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Z Squared Inc is a computing infrastructure company operating computing equipment and expanding into AI infrastructure. The Company's idea is to build on three principles: guide with power by acquiring operating sites where power is already flowing; build for AI workloads by converting that capacity into AI-ready colocation where the customer brings the compute and runs what it needs; and scale with discipline by deploying conversion capital site by site, against signed contracts and operational readiness.